甘李药业: 关于股份回购实施结果暨股份变动的公告

Core Points - The company announced a share repurchase plan with a total expected amount between RMB 150 million and RMB 300 million, with a maximum repurchase price of RMB 62.76 per share [1][2] - The actual number of shares repurchased is 3,540,021, representing 0.5890% of the total share capital, with a total expenditure of approximately RMB 150.07 million [3][4] - The purpose of the repurchased shares has been adjusted from employee stock ownership plans to cancellation and reduction of registered capital [2][3] Repurchase Plan Details - The repurchase period is from September 5, 2024, to September 4, 2025, and the company has complied with the regulations during the repurchase process [3][4] - The repurchase was conducted through centralized bidding, with the highest transaction price at RMB 45.14 per share and the lowest at RMB 37.65 per share, resulting in an average price of RMB 42.39 per share [3][4] - The company plans to cancel the repurchased shares on September 8, 2025, and will notify creditors regarding the capital reduction [6][7] Share Capital Changes - Before the repurchase, the total number of shares was 601,065,290, and after the cancellation of the repurchased shares, it will be reduced to 597,525,269 [6] - The repurchased shares will be canceled, leading to a decrease in the company's registered capital, which aligns with the long-term interests of the company and its investors [3][7]